KPF
ESLAW icon

K2 Principal Fund’s Estrella Immunopharma Warrant ESLAW Stock Holding History

K2 Principal Fund’s Portfolio ESLAW Stock Details ESLAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-118,936
Closed -$8.6K – 244
2023
Q1 		$8.6K Sell
118,936
-15,219
-11% -$994 ﹤0.01% 233
2022
Q4 		$6.98K Sell
134,155
-9,792
-7% -$819 ﹤0.01% 210
2022
Q3 		$10K Hold
143,947
– – ﹤0.01% 264
2022
Q2 		$36K Hold
143,947
– – ﹤0.01% 293
2022
Q1 		$32K Hold
143,947
– – ﹤0.01% 281
2021
Q4 		$72K Hold
143,947
– – ﹤0.01% 342
2021
Q3 		$59K Buy
+143,947
New +$59K ﹤0.01% 299

Other funds holding ESLAW

BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
ASM
ATW SPAC Management New York $79.2M AUM 10.67% 1-Year Est. Return
EFI
EHP Funds Inc Toronto, Canada $43.6M AUM 69.08% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
SIA
SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
WA
Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return

K2 Principal Fund's ESLAW Position: Q2 2023 in Review

K2 Principal Fund sold out of Estrella Immunopharma Warrant (ESLAW) in Q2 2023, closing a stake of 118,936 shares — an estimated $8.6K sold.

K2 Principal Fund first reported a position in ESLAW in Q3 2021 and held it in 7 quarters. The position peaked at $72K in Q4 2021. 19 funds tracked by Wall St. Rank hold ESLAW as of Q2 2023.

  • K2 Principal Fund reported no remaining Estrella Immunopharma Warrant position as of Q2 2023 after selling out during the quarter.
  • K2 Principal Fund sold 118,936 Estrella Immunopharma Warrant shares in Q2 2023, an estimated $8.6K.
  • K2 Principal Fund first reported a position in Estrella Immunopharma Warrant in Q3 2021 and held it in 7 quarters.
  • K2 Principal Fund's Estrella Immunopharma Warrant position peaked at $72K in Q4 2021.
  • 19 funds tracked by Wall St. Rank held Estrella Immunopharma Warrant as of Q2 2023.

Based on K2 Principal Fund's 13F filing for Q2 2023, filed 15 Aug 2023.